Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. announced that its Board of Directors has approved an amendment to the Company's Bylaws. Effective October 29, 2026, the amendment reduces the quorum requirement for all stockholder meetings to one-third (33.3%) of the voting power of the stock outstanding and entitled to vote, unless otherwise required by law or the Company's Certificate of Incorporation. Previously, a majority of the shares entitled to vote constituted a quorum.

Acurx Pharmaceuticals reported a net loss of $(2.25) million for the three months ended June 30, 2026, and $(3.94) million for the six months ended June 30, 2026. Despite raising $6.22 million through financing activities in the first half of 2026, the company's management has raised substantial doubt about its ability to continue as a going concern, citing insufficient cash to meet anticipated requirements for the next 12 months. The company continues to incur significant R&D expenses for its antibiotic candidates.

Acurx Pharmaceuticals reported a net loss of $(1.68) million for Q1 2026, an improvement from $(2.15) million in Q1 2025. The company's cash balance stood at $9.3 million as of March 31, 2026, which management believes is insufficient to meet anticipated cash requirements for the next 12 months, raising substantial doubt about its ability to continue as a going concern. The company continues to fund operations through equity financing, including $3.11 million from an equity line of credit in Q1 2026.

Acurx Pharmaceuticals filed an S-1 registration statement to register 1,300,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC, under a pre-existing Purchase Agreement. The company may receive up to an additional $4.7 million from Lincoln Park, supplementing the $7.3 million already received. This filing also highlights a recent $2.5 million registered direct offering and a new clinical development initiative for ibezapolstat in recurrent C. difficile infection, alongside details of a prior reverse stock split.

Acurx Pharmaceuticals, Inc. filed an S-1 registration statement for the resale of up to 1,650,170 shares of common stock by selling stockholders. These shares are issuable upon the exercise of series H warrants, which have an exercise price of $2.78 per share and were issued in a concurrent private placement on April 15, 2026. The company will not receive proceeds from the resale, but could receive approximately $4.6 million if all warrants are exercised for cash. Additionally, Acurx recently completed a registered direct offering, raising approximately $2.5 million, and announced a new clinical trial program for ibezapolstat in recurrent C. difficile infection.

Acurx Pharmaceuticals, Inc. entered into a Securities Purchase Agreement on April 15, 2026, for a registered direct offering. The company agreed to sell 816,068 shares of common stock at $3.03 per share and pre-funded common stock purchase warrants for up to 9,017 shares at $3.029 per share. This offering is expected to generate approximately $2.5 million in gross proceeds, which will be used for working capital and other general corporate purposes.